Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2603304 | 0.91 | KMT2A (0.44) | LMNAGAAMEN1KMT2ACYP2D6 | |
| SCHEMBL20328055 | 0.81 | MEN1 (0.43) | LMNAGAAMEN1KMT2ACYP2D6 | |
| SCHEMBL4778694 | 0.81 | LMNA (0.50) | LMNAMEN1KMT2ACYP2D6SMN1; SMN2 | |
| SCHEMBL20840303 | 0.81 | LMNA (0.50) | LMNAMEN1KMT2ACYP2D6SMN1; SMN2 | |
| SCHEMBL737197 | 0.81 | — | — | |
| SCHEMBL25437992 | 0.81 | MEN1 (0.43) | LMNAGAAMEN1KMT2ACYP2D6 | |
| SCHEMBL25436911 | 0.81 | MEN1 (0.43) | LMNAGAAMEN1KMT2ACYP2D6 | |
| SCHEMBL24726451 | 0.80 | ALDH1A1 (0.53) | GAAMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL18391573 | 0.80 | LMNA (0.48) | LMNAGAACYP2D6ALDH1A1CYP3A4 | |
| SCHEMBL7906446 | 0.80 | LMNA (0.48) | LMNAGAACYP2D6ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-12016864-B2 | LOX enzyme inhibiting methods and compositions | ANOVIA BIOSCIENCES, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12016864-B2 | LOX enzyme inhibiting methods and compositions | ANOVIA BIOSCIENCES, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018029-B2 | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-06-25 | — | — | US | disclosed |
| US-12018029-B2 | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-06-25 | — | — | US | disclosed |
| WO-2024035950-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| US-20100210659-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100016306-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | US | disclosed |
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-20090163463-A1 | Organic Compounds | NOVARTIS AG | 2009-06-25 | — | — | US | disclosed |
| US-20090163463-A1 | Organic Compounds | NOVARTIS AG | 2009-06-25 | — | — | US | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20050272036-A1 | Ketones | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | US | disclosed |
| CN-1681763-A | Chemical compounds | ASTRAZENECA AB (SE) | 2005-10-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | JAK1, JAK2, JAK3 | LMNA 4865/4885GAA 3102/4885MEN1 2160/4885 |
| US-12018029-B2 | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | LOX, LOXL1, LOXL3 | LMNA 983/4885GAA 867/4885MEN1 4448/4885 |
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | MERTK, DAPK1, AXL | LMNA 1982/4885GAA 965/4885MEN1 2456/4885 |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | MKI67, CCNI, CDKN1A | LMNA 2811/4885GAA 3192/4885MEN1 173/4885 |
| US-20100210659-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | OPRL1, OPRK1, OPRD1 | LMNA 4726/4885GAA 1229/4885MEN1 4851/4885 |
| US-20090163463-A1 | Organic Compounds | PIK3C3, PIK3CA, MTOR | LMNA 2944/4885GAA 720/4885MEN1 1530/4885 |
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | BRDT, BET1, BRD4 | LMNA 4759/4885GAA 2403/4885MEN1 2559/4885 |
| US-12016864-B2 | LOX enzyme inhibiting methods and compositions | LOX, LOXL1, LOXL2 | LMNA 518/4885GAA 124/4885MEN1 3610/4885 |
| US-20100016306-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | LMNA 4787/4885GAA 2467/4885MEN1 4216/4885 |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | KDM1A, TET1, KDM3A | LMNA 1527/4885GAA 531/4885MEN1 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.